CytomX Therapeutics (CTMX) Change in Acquisitions & Divestments (2015 - 2026)

CytomX Therapeutics (CTMX) has 12 years of Change in Acquisitions & Divestments data on file, last reported at $50.0 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 0.99% year-over-year to $50.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132.5 million (down 49.23% YoY) and the FY2025 annual result came in at $133.0 million, down 47.95% from the prior year.
• Change in Acquisitions & Divestments grew to $50.0 million in Q1 2026, from $30.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $125.0 million in Q4 2023 to a low of $20.0 million in Q3 2025.
• A 5-year average of $62.6 million and a median of $50.0 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments rose 25.0% — and 2025, when it slumped 71.74%.
• Tracing CTMX's Change in Acquisitions & Divestments over 5 years: stood at $100.0 million in 2022, then climbed by 25.0% to $125.0 million in 2023, then plunged by 48.0% to $65.0 million in 2024, then sank by 53.85% to $30.0 million in 2025, then soared by 66.67% to $50.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $50.0 million (Q1 2026), $30.0 million (Q4 2025), and $20.0 million (Q3 2025), per Business Quant data.